276 related articles for article (PubMed ID: 29879966)
1. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
Suh HS; Kim JA; Lee IH
BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
[TBL] [Abstract][Full Text] [Related]
2. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
[TBL] [Abstract][Full Text] [Related]
3. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
Kang SO; Kim SJ; Park S; Jang SI; Park EC
Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
[TBL] [Abstract][Full Text] [Related]
4. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea.
Kwon HY; Bae S; Choi SE; Park S; Lee EK; Park S; Kim J
Health Policy; 2019 Apr; 123(4):388-392. PubMed ID: 30503763
[TBL] [Abstract][Full Text] [Related]
5. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
Usher C; Tilson L; Bennett K; Barry M
Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
[TBL] [Abstract][Full Text] [Related]
6. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
[TBL] [Abstract][Full Text] [Related]
7. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
8. National trends in prescription drug expenditures and projections for 2021.
Tichy EM; Hoffman JM; Suda KJ; Rim MH; Tadrous M; Cuellar S; Clark JS; Wiest MD; Matusiak LM; Schumock GT
Am J Health Syst Pharm; 2021 Jul; 78(14):1294-1308. PubMed ID: 33880494
[TBL] [Abstract][Full Text] [Related]
9. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
Kwon HY; Hong JM; Godman B; Yang BM
Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
[TBL] [Abstract][Full Text] [Related]
10. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
11. Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea.
Jo JS; Kim YM; Paek KW; Bea MH; Chun K; Lee S
Yonsei Med J; 2016 Jul; 57(4):1016-21. PubMed ID: 27189299
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Price-Volume Agreement Program in South Korea.
Han E; Park SY; Lee EK
Health Policy; 2016 Oct; 120(10):1209-1215. PubMed ID: 27519975
[TBL] [Abstract][Full Text] [Related]
13. Effects of pharmaceutical cost containment policies on doctors' prescribing behavior: Focus on antibiotics.
Han E; Chae SM; Kim NS; Park S
Health Policy; 2015 Sep; 119(9):1245-54. PubMed ID: 26119997
[TBL] [Abstract][Full Text] [Related]
14. [How AMOG limits the supply of diabetes drugs].
Oberhofer E
MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
[No Abstract] [Full Text] [Related]
15. Pharmaceutical reform in South Korea and the lessons it provides.
Kim HJ; Ruger JP
Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
[TBL] [Abstract][Full Text] [Related]
16. Twenty-year trends in the prescription costs of Type 2 diabetes: Real world data and empirical analysis in Greece.
Athanasakis K; Prodromiadou E; Papazafiropoulou A; Koutsovasilis A; Driva S; Ziori M; Georgopoulos E; Gougourelas D; Sotiropoulos A; Bousboulas S; Melidonis A; Liatis S
Diabetes Res Clin Pract; 2020 Apr; 162():108095. PubMed ID: 32112790
[TBL] [Abstract][Full Text] [Related]
17. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
Lee IH; Bloor K; Hewitt C; Maynard A
Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
[TBL] [Abstract][Full Text] [Related]
18. Copayment policy effects on healthcare spending and utilization by Korean lung cancer patients at end of life: a retrospective cohort design 2003-2012.
Kim SJ; Han KT; Park EC; Park S; Kim TH
Asian Pac J Cancer Prev; 2014; 15(13):5265-70. PubMed ID: 25040986
[TBL] [Abstract][Full Text] [Related]
19. The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study.
Ding L; Wu J
Value Health; 2017 Mar; 20(3):412-419. PubMed ID: 28292486
[TBL] [Abstract][Full Text] [Related]
20. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.
Neilson LM; Munshi KD; Peasah SK; Huang Y; Swart ECS; Henderson R; Manolis C; Good CB
Med Care; 2021 Sep; 59(9):789-794. PubMed ID: 34183622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
